Cytotherapy · 2025
Incidence, risk factors and clinical outcomes of primary prolonged isolated thrombocytopenia following haploidentical transplantation for severe aplastic anemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Ming-Hao, Sun Wei, Huang Xiao-Jun, Xu Lan-Ping, Wang Yu, Zhang Xiao-Hui, Cheng Yi-Fei, Zhang Yuan-Yuan, Mo Xiao-Dong, Sun Yu-Qian, Han Ting-Ting, Wang Jing-Zhi, Chen Yao, Chen Yu-Hong, Chen Huan, Han Wei, Xu Zheng-Li
Аннотация
BACKGROUND AIMS: While primary prolonged isolated thrombocytopenia (PT) represents a common complication after haploidentical hematopoietic stem cell transplantation (haplo-HSCT), its clinical significance in severe aplastic anemia (SAA) patients remains underexplored. This study aims to characterize the incidence, prognostic impact and risk factors of PT in SAA patients undergoing haplo-HSCT.
METHODS: The authors retrospectively analyzed the clinical data of 502 patients diagnosed with SAA who underwent haplo-HSCT at our institution between January 2006 and December 2022.
RESULTS: The cumulative incidence of primary PT was 7.6% (38/502). Primary PT significantly correlated with inferior long-term outcomes, demonstrating markedly reduced 5-year overall survival (65.8% vs. 94.1%, P < 0.001) and graft-versus-host disease (GvHD)-free, failure-free survival (44.7% vs. 83.3%, P < 0.001) compared to non-PT counterparts. Multivariate analysis revealed five independent risk factors: pretransplant red blood cell transfusion burden ≥40 units, maternal donor, infused CD34+ cell dose <2 × 10⁶/kg, grade II-IV acute GvHD and refractory cytomegalovirus viremia. A risk stratification model incorporating these factors showed discriminative capacity, with primary PT incidence escalating from 2.3% (low-risk: 0 factors) to 6.9% (intermediate-risk: 1-2 factors) and 31.7% (high-risk: 3-5 factors) (P < 0.001).
CONCLUSIONS: This study establishes primary PT as an independent prognostic marker in SAA patients receiving haplo-HSCT. The developed risk model may facilitate early identification of high-risk patients requiring intensified monitoring and preemptive interventions.
METHODS: The authors retrospectively analyzed the clinical data of 502 patients diagnosed with SAA who underwent haplo-HSCT at our institution between January 2006 and December 2022.
RESULTS: The cumulative incidence of primary PT was 7.6% (38/502). Primary PT significantly correlated with inferior long-term outcomes, demonstrating markedly reduced 5-year overall survival (65.8% vs. 94.1%, P < 0.001) and graft-versus-host disease (GvHD)-free, failure-free survival (44.7% vs. 83.3%, P < 0.001) compared to non-PT counterparts. Multivariate analysis revealed five independent risk factors: pretransplant red blood cell transfusion burden ≥40 units, maternal donor, infused CD34+ cell dose <2 × 10⁶/kg, grade II-IV acute GvHD and refractory cytomegalovirus viremia. A risk stratification model incorporating these factors showed discriminative capacity, with primary PT incidence escalating from 2.3% (low-risk: 0 factors) to 6.9% (intermediate-risk: 1-2 factors) and 31.7% (high-risk: 3-5 factors) (P < 0.001).
CONCLUSIONS: This study establishes primary PT as an independent prognostic marker in SAA patients receiving haplo-HSCT. The developed risk model may facilitate early identification of high-risk patients requiring intensified monitoring and preemptive interventions.